NEW YORK, Jan. 29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
CNS Therapeutics - A World Market Review
http://www.reportlinker.com/p0164268/CNS-Therapeutics---A-World-Market-Review.html
While the available CNS therapies can slow down deteriorating condition of patient, the clinical pipeline boasts of new drug classes with potential to stop or reverse the disease's progression. Continuing switch over of patients from typical or traditional anti-psychotics to expensive and safer atypical anti-psychotics drugs, such as Zyprexa, Risperdal and Geodon is driving the market forward. Global market for anti-depressants, a dominant product category of CNS therapeutics is on a decline, succumbed by increasing generic competition, loss of patent protection of key drugs, and increased risk of suicidal tendencies among adolescents.
These and other market data and trends are presented in "CNS Therapeutics: World Market Review" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses
CNS THERAPEUTICS BMR-1068
CONTENTS
1. METHODOLOGY 1
Study Reliability and Reporting Limitations 1
Disclaimers 2
Quantitative Techniques & Reporting Level 3
2. GLOBAL MARKET OVERVIEW AND OUTLOOK 4
Factors Influencing Demand 4
The 'Age Factor' 4
Role of Diagnostic Techniques 4
Increasing Disease Awareness 4
Emergent Technologies 4
Reimbursement Policies 5
Outlook 5
Market Trends and Issues 5
Booming Therapeutic Opportunities for Neuro-Degenerative
Disorders 5
Spur in CNS Drug Delivery Technologies 6
Migraine Market Offers Growth Opportunities to Prophylaxis
Products 7
Demand for Therapeutic Peptides Spurred by Dearth of
Effective Therapies 7
Anti-Depressants 7
Major Trends in the Depression Market 8
SSRIs are the Preferred Choice Despite Side Effects 8
Attention Deficit Hyperactivity Disorder (ADHD) 9
Major Trends in the ADHD Market 9
Anti-Psychotics Market 10
Restrictions on Promotion Hamper Market Prospects 10
Insomnia 11
Anti-Insomnia Drugs from Corporate Giants Flood the Sleep
Market 11
Neuropathic Pain 11
Patent Expiry of Leading CNS Drugs: 2005-2017 12
3. PRODUCT FACTS 13
CNS Disorders 13
A. Anti-Alzheimer's Drugs 13
B. Anti-Parkinson's Drugs 13
C. Anti-Epilepsy Drugs 14
D. Pain Management Drugs 14
E. Anti-Psychotics Drugs 14
(i) Bipolar disorder 14
(ii) Schizophrenia 14
F. Anti-Depressants Drugs 15
G. Others 15
(i) Attention Deficit Hyperactivity Disorder 15
(ii) Multiple Sclerosis 16
(iii) Insomnia 16
(iv) Restless Legs Syndrome 16
(v) Anxiety 17
4. CORPORATE DEVELOPMENTS 18
P1vital Creates Global Consortium to Develop CNS Experimental
Medicine 18
Neurobiological Tech Teams Up with Buck Institute 18
ExonHit Therapeutics and Allergan Ink Contract to Develop CNS
Agents 18
NeuroSearch Commences Clinical Phase I study with NSD-788 in
France 18
Abilify® Meets CHMP Standards 18
UCB Receives Recommendation for Approval for Neupro® 19
Schering-Plough Acquires Organon 19
UCB Launches Neupro® in the US 19
GlaxoSmithKline Forms Alliance with Targacept 19
GSK Teams-Up with Sepracor for Commercializing Lunivia® 20
US FDA Rebut NDA for bifeprunox 20
Medtronic and Alnylam Extend their Drug- Device Collaboration 20
Neuren Takes Over Hamilton 20
Roche Forms Partnership with Synosis Therapeutics to Evaluate
Five CNS Compounds 20
NeuroSearch Starts Clinical Phase I Study with ACR343 in Sweden 21
Lundbeck to Promote Circadin® in Europe 21
Sepracor Inks Partnership with Eisai to Develop and Market 21
Lunesta® in Japan 21
5. MAJOR PLAYERS 21
Abbott Laboratories (USA) 21
Alkermes, Inc. (USA) 22
AstraZeneca Plc (UK) 22
Boehringer Ingelheim GmbH (Germany) 22
Bristol-Myers Squibb (USA) 22
Cephalon, Inc. (USA) 23
Dainippon Sumitomo Pharma Co., Ltd. (Japan) 23
Elan Corporation Plc (Ireland) 23
Eli Lilly and Co. (USA) 23
Fabre-Kramer Pharmaceuticals, Inc. (USA) 24
F. Hoffmann-La Roche Ltd. (Switzerland) 24
Forest Laboratories, Inc. (USA) 24
GlaxoSmithKline (UK) 24
H. Lundbeck A/S (Denmark) 24
Johnson & Johnson (USA) 25
Janssen Pharmaceutica N.V. (Belgium) 25
Janssen-Cilag (Switzerland) 25
Merck & Co., Inc. (USA) 25
Neurocrine Biosciences, Inc. (USA) 25
Novartis AG (Switzerland) 25
Sandoz International GmbH (Germany) 26
Organon N.V. (The Netherlands) 26
Ortho-McNeil Neurologics, Inc. (USA) 26
Otsuka Pharmaceutical Co., Ltd. (Japan) 26
Pfizer, Inc. (USA) 27
Sanofi-Aventis (France) 27
Schwarz Pharma AG (Germany) 27
Sepracor, Inc. (USA) 27
Shire Plc (UK) 27
Solvay Pharmaceuticals S.A. (Belgium) 28
Takeda Pharmaceutical Co., Ltd. (Japan) 28
Teva Pharmaceutical Industries Ltd. (Israel) 28
UCB S.A. (Belgium) 28
Wyeth (USA) 29
6. GLOBAL MARKET ANALYTICS 29
7. THE UNITED STATES 37
Cost Implications of CNS Disorders 37
Alzheimer's Market 38
Anti-Alzheimer's Drugs Approved for Use in the Past 38
Cost of Care to AD Patient 39
Clinical Pipeline 39
Anti-Psychotics 39
Growth Dampeners 39
Clinical Pipeline 40
Antidepressants 41
Antidepressants to Feature Black-Box Warnings 41
Antidepressant Consumption Falls Among Children and Adolescents 41
Multiple Sclerosis 42
Insomnia Market 42
Rising Consumption of ADHD Drugs Combat Safety Concerns 42
Unmet Medical Needs in Neuropathic Pain Offer Growth Prospects 43
CNS Tuberculosis Raises its Ugly Head 43
8. CANADA 45
Facts & Figures 45
9. EUROPE 47
a. France 51
b. Germany 52
c. Italy 54
d. The United Kingdom 56
e. Spain 58
f. Rest of Europe 59
10. ASIA-PACIFIC 62
An Overview of the Japanese Market 62
Pain Management Market 62
11. LATIN AMERICA 64
12. REST OF WORLD 65
EXHIBITS
Table 1: Sales of Leading ADHD Drug Brands in the World - 2005
(In US$M)
Table 2: Sales of Leading Atypical Anti- Psychotic Drug Brands
in the World - 2005 (In US$ Million)
Table 3: Percentage Breakdown of Leading Anti-Psychotics
Brands Value Sales in the World - 2005
Table 4: Percentage Breakdown of Leading Anti-Parkinson's
Disease Brands Value Sales in the World - 2005
Table 5: Sales of Leading Epilepsy Drug Brands in the World -
2005 (In US$ Million)
Table 6: Global CNS Therapeutics Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 7: Percentage Breakdown of Global CNS Therapeutics
Market by Region for the Years 2008 & 2012
Table 8: Global Anti-Alzheimer's Drugs Market by Region for
the Period 2007- 2015 (Sales in US$ Million)
Table 9: Percentage Breakdown of Global Anti-Alzheimer's Drugs
Market by Region for the Years 2008 & 2012
Table 10: Global Anti-Parkinson's Drugs Market by Region for
the Period 2007- 2015 (Sales in US$ Million)
Table 11: Percentage Breakdown of Global Anti-Parkinson's
Drugs Market by Region for the Years 2008 & 2012
Table 12: Global Anti-Epilepsy Drugs Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 13: Percentage Breakdown of Global Anti-Epilepsy Drugs
Market by Region for the Years 2008 & 2012
Table 14: Global Pain Management Drugs Market by Region for
the Period 2007- 2015 (Sales in US$ Million)
Table 15: Percentage Breakdown of Global Pain Management Drugs
Market by Region for the Years 2008 & 2012
Table 16: Global Anti-Psychotics Drugs Market by Region for
the Period 2007-2015 (Sales in US$ Million)
Table 17: Percentage Breakdown of Global Anti-Psychotics Drugs
Market by Region for the Years 2008 & 2012
Table 18: Global Anti-Depressants Drugs Market by Region for
the Period 2007-2015 (Sales in US$ Million)
Table 19: Percentage Breakdown of Global Anti-Depressants
Drugs Market by Region for the Years 2008 & 2012
Table 20: Global Other CNS Drugs Market by Region for the
Period 2007-2015 (Sales in US$ Million)
Table 21: Percentage Breakdown of Global Other CNS Drugs
Market by Region for the Years 2008 & 2012
Table 22: Percentage Breakdown of Leading Alzheimer Brands
Value Sales in the US - 2005
Table 23: Percentage Breakdown of Leading Anti-Psychotics
Brands Value Sales in the US - 2006
Table 24: Percentage Breakdown of Leading Atypical
Anti-Psychotic Brands Value Sales in the US - 2008
Table 25: Sales of Leading Antidepressant Drug Brands in the
US - 2006 (In US$M)
Table 26: Percentage Breakdown of Leading Anti-Multiple
Sclerosis Drug Brands Value Sales in the US - 2004
Table 27: Percentage Breakdown of Leading ADHD Brands Sales
in the US - 2005
Table 28: Percentage Breakdown of Leading Pain Management
Manufacturers Value Sales in the US - 2007
Table 29: CNS Therapeutics Market by Segment in the US:
2007-2015 (Sales in US$ Million)
Table 30: Percentage Breakdown of CNS Therapeutics Market by
Segment in the US for the Years 2008 & 2012
Table 31: CNS Therapeutics Market by Segment in Canada:
2007-2015 (Sales in US$ Million)
Table 32: Percentage Breakdown of CNS Therapeutics Market by
Segment in Canada for the Years 2008 & 2012
Table 33: Percentage Breakdown of Anti-Psychotics Market
Revenues by Product Class in Europe - 2006
Table 34: Percentage Breakdown of Leading Atypical
Anti-Psychotics Brand Value Sales in Europe - 2004
Table 35: Percentage Breakdown of Leading Anti-Depressant
Brands Value Sales in Europe - 2005
Table 36: Percentage Breakdown of Antidepressants Market
Revenues by Segment in Europe - 2006
Table 37: CNS Therapeutics Market by Region in Europe:
2007-2015 (Sales in US$ Million)
Table 38: Percentage Breakdown of CNS Therapeutics Market by
Region in Europe for the Years 2008 & 2012
Table 39: CNS Therapeutics Market by Segment in Europe:
2007-2015 (Sales in US$ Million)
Table 40: Percentage Breakdown of CNS Therapeutics Market by
Segment in Europe for the Years 2008 & 2012
Table 41: CNS Therapeutics Market by Segment in France:
2007-2015 (Sales in US$ Million)
Table 42: Percentage Breakdown of CNS Therapeutics Market by
Segment in France for the Years 2008 & 2012
Table 43: CNS Therapeutics Market by Segment in Germany:
2007-2015 (Sales in US$ Million)
Table 44: Percentage Breakdown of CNS Therapeutics Market by
Segment in Germany for the Years 2008 & 2012
Table 45: CNS Therapeutics Market by Segment in Italy:
2007-2015 (Sales in US$ Million)
Table 46: Percentage Breakdown of CNS Therapeutics Market by
Segment in Italy for the Years 2008 & 2012
Table 47: CNS Therapeutics Market by Segment in the UK:
2007-2015 (Sales in US$ Million)
Table 48: Percentage Breakdown of CNS Therapeutics Market by
Segment in the UK for the Years 2008 & 2012
Table 49: CNS Therapeutics Market by Segment in Spain:
2007-2015 (Sales in US$ Million)
Table 50: Percentage Breakdown of CNS Therapeutics Market by
Segment in Spain for the Years 2008 & 2012
Table 51: CNS Therapeutics Market by Segment in Rest of
Europe: 2007- 2015 (Sales in US$ Million)
Table 52: Percentage Breakdown of CNS Therapeutics Market by
Segment in Rest of Europe for the Years 2008 & 2012
Table 53: CNS Therapeutics Market by Segment in Asia-Pacific:
2007-2015 (Sales in US$ Million)
Table 54: Percentage Breakdown of CNS Therapeutics Market by
Segment in Asia-Pacific for the Years 2008 & 2012
Table 55: CNS Therapeutics Market by Segment in Latin America:
2007-2015 (Sales in US$ Million)
Table 56: Percentage Breakdown of CNS Therapeutics Market by
Segment in Latin America for the Years 2008 & 2012
Table 57: CNS Therapeutics Market by Segment in Rest of World:
2007- 2015 (Sales in US$ Million)
Table 58: Percentage Breakdown of CNS Therapeutics Market by
Segment in Rest of World for the Years 2008 & 2012
COMPANIES PROFILED
To order this report:
Pharmaceutical Industry: CNS Therapeutics - A World Market Review
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article